Cargando…
The Translation and Commercialisation of Biomarkers for Cardiovascular Disease—A Review
As a leading cause of mortality and morbidity worldwide, cardiovascular disease and its diagnosis, quantification, and stratification remain significant health issues. Increasingly, patients present with cardiovascular disease in the absence of known risk factors, suggesting the presence of yet unre...
Autores principales: | Saleh, Soloman, George, Jacob, Kott, Katharine A., Meikle, Peter J., Figtree, Gemma A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201254/ https://www.ncbi.nlm.nih.gov/pubmed/35722087 http://dx.doi.org/10.3389/fcvm.2022.897106 |
Ejemplares similares
-
Biobanking for discovery of novel cardiovascular biomarkers using imaging-quantified disease burden: protocol for the longitudinal, prospective, BioHEART-CT cohort study
por: Kott, Katharine A, et al.
Publicado: (2019) -
Nanotechnology commercialisation
por: Tsuzuki, Takuya
Publicado: (2013) -
Editorial: Clinical Translation and Commercialisation of Advanced Therapy Medicinal Products
por: Martin, Ivan, et al.
Publicado: (2020) -
Biomarker Development in Cardiology: Reviewing the Past to Inform the Future
por: Kott, Katharine A., et al.
Publicado: (2022) -
Sortilin as a Biomarker for Cardiovascular Disease Revisited
por: Møller, Peter Loof, et al.
Publicado: (2021)